Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide. Open. Download Table | Schema for CALGB trial CALGB trial schema from publication: Small Cell Lung Cancer: Have We Made Any Progress Over the . This randomized phase III trial is comparing three different chest radiation therapy regimens to see how well they work in treating patients with limited-stage .

Author: Zurn Grojas
Country: Gambia
Language: English (Spanish)
Genre: Career
Published (Last): 2 September 2016
Pages: 161
PDF File Size: 6.74 Mb
ePub File Size: 8.34 Mb
ISBN: 840-1-58129-336-9
Downloads: 84763
Price: Free* [*Free Regsitration Required]
Uploader: Faeshakar

By Alice Goodman June 25, Advertisement.

It evaluated the optimization of chemoradiotherapy in limited-stage SCLC. Median overall survival was 30 months vs 25 months, a difference that is not statistically significant. calhb

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

It was challenging to accrue patients with this disease. In this trial, survival was higher than previously reported in other trials of this patient population, and radiation toxicities were lower than expected.


The study enrolled patients with histologically or cytologically proven SCLC recruited from 73 centers in 7 European countries and Canada between and Patients with any response were offered prophylactic cranial radiation therapy. All analyses were done on an intention-to-treat basis. A total of 25 patients in the twice-daily radiation therapy group and 32 in the once-daily radiation therapy group did not get concurrent chemoradiation therapy.

Eighty percent of patients had stage III disease. There was no statistically significant overall survival difference between the groups.

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

No statistically significant differences between the two groups were reported for the rates of progression-free survival or local or metastatic disease progression. Adverse events were not significantly different between the two groups as well, with the exception of more neutropenia in patients treated with twice-daily radiation therapy.

High-dose radiation therapy to the lungs and esophagus in the once-daily arm did not seem to translate cxlgb a significant difference between the arms in terms of esophagitis or pneumonitis. There was one death in the twice-daily group and two in the once-daily group due to radiation pneumonitis. An international randomised trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer and good performance status.


Taofeek Kunle Owonikoko, MD. Formal discussant Taofeek Kunle Owonikoko, MDof Winship Cancer Institute of Emory University, Atlanta, said it has been controversial whether to use once-daily or twice-daily radiation therapy in this patient population. Survival in both arms was higher than previously reported. Radiation-related toxicities were lower than expected likely due to the use of modern RT techniques These inconclusive results suggest that either schedule can be used in this setting.

Expert Point of View: Clinical Applications of Genomic Studies R. Seidman, MD, and Charles E. Updated Trial Findings View More.